AdCLD-CoV19

AdCLD-CoV19
Vaccine description
Target	SARS-CoV-2
Vaccine type	Viral vector
Clinical data
Routes of; administration	Intramuscular
Identifiers
CAS Number	2698316-99-1;

AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,^[2]^[3] a company from South Korea.^[4]

A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea.^[5] In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.^[6] Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022.^[7] In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.^[8]

References

^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
^ Chan-Hyuk K (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review. Retrieved 22 August 2021.
^ Chan-hyuk K (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review. Retrieved 22 August 2021.
^ "Cellid Co Ltd, Company Profile and News". Bloomberg Markets.
^ Clinical trial number NCT04666012 for "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers" at ClinicalTrials.gov
^ Cellid Co (21 January 2022). "A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.
^ Shin SP, Shin KS, Lee JM, Jung IK, Koo J, Lee SW, et al. (April 2022). "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates". Vaccines. 10 (5): 712. doi:10.3390/vaccines10050712. PMC 9147121. PMID 35632468.
^ Cellid Co (27 August 2022). "A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.

[1] "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).

[2] Chan-Hyuk K (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review. Retrieved 22 August 2021.

[3] Chan-hyuk K (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review. Retrieved 22 August 2021.

[4] "Cellid Co Ltd, Company Profile and News". Bloomberg Markets.

[Trial_registration_NCT04666012-5] Clinical trial number NCT04666012 for "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers" at ClinicalTrials.gov

[Trial_registration_NCT05047692-6] Cellid Co (21 January 2022). "A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.

[Preclinical_2022-7] Shin SP, Shin KS, Lee JM, Jung IK, Koo J, Lee SW, et al. (April 2022). "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates". Vaccines. 10 (5): 712. doi:10.3390/vaccines10050712. PMC 9147121. PMID 35632468.

[Registration_phase_2_trial_NCT05520970-8] Cellid Co (27 August 2022). "A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

COVID-19 pandemic
Part of a series on the

COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society African diaspora Animals Alzheimer's disease patients Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBTQ community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal